Company intelligence / Profile preview

Altair Therapeutics, Inc.

San Diego, California, United Statesprofiles.biocentury.com ↗

Ownership: Private
Employees: ~7
Development stage: Phase 1

Overview

Altair Therapeutics' lead drug candidate AIR645 failed to show enough evidence of benefit in asthma patients in a mid-stage clinical trial. The company was subsequently shut down in early 2011.

Therapeutic areas: Pulmonology
Modalities: Antisense drugs
Industry: Biotech

Drug pipeline

1 asset

AIR645

Phase 1

Indications: Asthma, Allergic rhinitis

Partnerships

Isis Pharmaceuticals (now Ionis Pharmaceuticals)

Beyond the preview

Go deeper on Altair Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Altair Therapeutics, Inc..

Explore the full profile